These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 35758897)

  • 21. A new glimpse on the active site of SARS-CoV-2 3CLpro, coupled with drug repurposing study.
    Novak J; Potemkin VA
    Mol Divers; 2022 Oct; 26(5):2631-2645. PubMed ID: 35001230
    [TBL] [Abstract][Full Text] [Related]  

  • 22. 3-Chymotrypsin-like Protease (3CLpro) of SARS-CoV-2: Validation as a Molecular Target, Proposal of a Novel Catalytic Mechanism, and Inhibitors in Preclinical and Clinical Trials.
    Amorim VMF; Soares EP; Ferrari ASA; Merighi DGS; de Souza RF; Guzzo CR; Souza AS
    Viruses; 2024 May; 16(6):. PubMed ID: 38932137
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A highly sensitive cell-based luciferase assay for high-throughput automated screening of SARS-CoV-2 nsp5/3CLpro inhibitors.
    Chen KY; Krischuns T; Varga LO; Harigua-Souiai E; Paisant S; Zettor A; Chiaravalli J; Delpal A; Courtney D; O'Brien A; Baker SC; Decroly E; Isel C; Agou F; Jacob Y; Blondel A; Naffakh N
    Antiviral Res; 2022 May; 201():105272. PubMed ID: 35278581
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 3C-like protease inhibitors block coronavirus replication in vitro and improve survival in MERS-CoV-infected mice.
    Rathnayake AD; Zheng J; Kim Y; Perera KD; Mackin S; Meyerholz DK; Kashipathy MM; Battaile KP; Lovell S; Perlman S; Groutas WC; Chang KO
    Sci Transl Med; 2020 Aug; 12(557):. PubMed ID: 32747425
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High-throughput screening identifies inhibitors of the SARS coronavirus main proteinase.
    Blanchard JE; Elowe NH; Huitema C; Fortin PD; Cechetto JD; Eltis LD; Brown ED
    Chem Biol; 2004 Oct; 11(10):1445-53. PubMed ID: 15489171
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Overview of antiviral drug candidates targeting coronaviral 3C-like main proteases.
    Chen CC; Yu X; Kuo CJ; Min J; Chen S; Ma L; Liu K; Guo RT
    FEBS J; 2021 Sep; 288(17):5089-5121. PubMed ID: 33400393
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In silico analysis and identification of antiviral coumarin derivatives against 3-chymotrypsin-like main protease of the novel coronavirus SARS-CoV-2.
    Abdizadeh R; Hadizadeh F; Abdizadeh T
    Mol Divers; 2022 Apr; 26(2):1053-1076. PubMed ID: 34213728
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development of a simple, interpretable and easily transferable QSAR model for quick screening antiviral databases in search of novel 3C-like protease (3CLpro) enzyme inhibitors against SARS-CoV diseases.
    Kumar V; Roy K
    SAR QSAR Environ Res; 2020 Jul; 31(7):511-526. PubMed ID: 32543892
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Study of Drug Repurposing to Identify SARS-CoV-2 Main Protease (3CLpro) Inhibitors.
    Jo S; Signorile L; Kim S; Kim MS; Huertas O; Insa R; Reig N; Shin DH
    Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35742913
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A head-to-head comparison of the inhibitory activities of 15 peptidomimetic SARS-CoV-2 3CLpro inhibitors.
    Vankadara S; Wong YX; Liu B; See YY; Tan LH; Tan QW; Wang G; Karuna R; Guo X; Tan ST; Fong JY; Joy J; Chia CSB
    Bioorg Med Chem Lett; 2021 Sep; 48():128263. PubMed ID: 34271072
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeting the Dimerization of the Main Protease of Coronaviruses: A Potential Broad-Spectrum Therapeutic Strategy.
    Goyal B; Goyal D
    ACS Comb Sci; 2020 Jun; 22(6):297-305. PubMed ID: 32402186
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Synthetic and computational efforts towards the development of peptidomimetics and small-molecule SARS-CoV 3CLpro inhibitors.
    Paul A; Sarkar A; Saha S; Maji A; Janah P; Kumar Maity T
    Bioorg Med Chem; 2021 Sep; 46():116301. PubMed ID: 34332853
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Substitutions L50F, E166A, and L167F in SARS-CoV-2 3CLpro Are Selected by a Protease Inhibitor
    Jochmans D; Liu C; Donckers K; Stoycheva A; Boland S; Stevens SK; De Vita C; Vanmechelen B; Maes P; Trüeb B; Ebert N; Thiel V; De Jonghe S; Vangeel L; Bardiot D; Jekle A; Blatt LM; Beigelman L; Symons JA; Raboisson P; Chaltin P; Marchand A; Neyts J; Deval J; Vandyck K
    mBio; 2023 Feb; 14(1):e0281522. PubMed ID: 36625640
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Characterization of trans- and cis-cleavage activity of the SARS coronavirus 3CLpro protease: basis for the in vitro screening of anti-SARS drugs.
    Lin CW; Tsai CH; Tsai FJ; Chen PJ; Lai CC; Wan L; Chiu HH; Lin KH
    FEBS Lett; 2004 Sep; 574(1-3):131-7. PubMed ID: 15358553
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The SARS-CoV-2 main protease doesn't induce cell death in human cells in vitro.
    Komissarov A; Karaseva M; Roschina M; Kostrov S; Demidyuk I
    PLoS One; 2022; 17(5):e0266015. PubMed ID: 35609027
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Genetic Surveillance of SARS-CoV-2 M
    Lee JT; Yang Q; Gribenko A; Perrin BS; Zhu Y; Cardin R; Liberator PA; Anderson AS; Hao L
    mBio; 2022 Aug; 13(4):e0086922. PubMed ID: 35862764
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cinanserin is an inhibitor of the 3C-like proteinase of severe acute respiratory syndrome coronavirus and strongly reduces virus replication in vitro.
    Chen L; Gui C; Luo X; Yang Q; Günther S; Scandella E; Drosten C; Bai D; He X; Ludewig B; Chen J; Luo H; Yang Y; Yang Y; Zou J; Thiel V; Chen K; Shen J; Shen X; Jiang H
    J Virol; 2005 Jun; 79(11):7095-103. PubMed ID: 15890949
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Merbromin is a mixed-type inhibitor of 3-chyomotrypsin like protease of SARS-CoV-2.
    Chen J; Zhang Y; Zeng D; Zhang B; Ye X; Zeng Z; Zhang XK; Wang Z; Zhou H
    Biochem Biophys Res Commun; 2022 Feb; 591():118-123. PubMed ID: 35007835
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of apigenin-based biflavonoid derivatives as potential therapeutic agents against viral protease (3CLpro) of SARS-CoV-2 via molecular docking, molecular dynamics and quantum mechanics studies.
    Abdizadeh R; Hadizadeh F; Abdizadeh T
    J Biomol Struct Dyn; 2023; 41(13):5915-5945. PubMed ID: 35848354
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Biochemical and biophysical characterization of the main protease, 3-chymotrypsin-like protease (3CLpro) from the novel coronavirus SARS-CoV 2.
    Ferreira JC; Rabeh WM
    Sci Rep; 2020 Dec; 10(1):22200. PubMed ID: 33335206
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.